ContraFect_LOGO_Web.jpg
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
June 17, 2021 07:30 ET | ContraFect Corporation
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
May 26, 2021 07:30 ET | ContraFect Corporation
Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function The observed clinical responses in patients...
ContraFect_LOGO_Web.jpg
ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit
April 15, 2021 18:30 ET | ContraFect Corporation
YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 30, 2021 07:30 ET | ContraFect Corporation
Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research...
ContraFect_LOGO_Web.jpg
ContraFect Corporation Announces Proposed Public Offering of Common Stock
March 17, 2021 16:01 ET | ContraFect Corporation
YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect_LOGO_Web.jpg
ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update
November 13, 2020 08:33 ET | ContraFect Corporation
CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections Initiated expanded access program with exebacase for the...
ContraFect_LOGO_Web.jpg
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients
October 26, 2020 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 07:30 ET | ContraFect Corporation
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering,...
ContraFect_LOGO_Web.jpg
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
June 17, 2020 07:30 ET | ContraFect Corporation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...
ContraFect_LOGO_Web.jpg
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
June 15, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...